- At least 2 prior regimens and no more than 5, which must include at least 1 approved proteasome inhibitor (bortezomib or carfilzomib) and at least 1 approved immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide), with or without maintenance therapy, unless patients are ineligible to receive such agents.